Exagen Inc.
NASDAQ:XGN
2.75 (USD) • At close November 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Exagen Inc. |
Symbool | XGN |
Munteenheid | USD |
Prijs | 2.75 |
Beurswaarde | 47,812,600 |
Dividendpercentage | 0% |
52-weken bereik | 1.3 - 3.71 |
Industrie | Diagnostics & Research |
Sector | Healthcare |
CEO | Mr. John Aballi |
Website | https://www.exagen.com |
An error occurred while fetching data.
Over Exagen Inc.
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)